MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer



Status:Recruiting
Conditions:Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:11/11/2012
Start Date:April 2011
Contact:Joyce Liu, MD
Email:joyce_liu@dfci.harvard.edu
Phone:617-632-5269

Use our guide to learn which trials are right for you!

A Phase II Study of MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer


MK-2206 is a drug that may stop cancer cells from growing by blocking a protein called AKT
inside the cell. AKT interacts with other proteins in the cell that are part of the P13K/AKT
pathway, a pathway that is know to play a role in the growth of cancer cells. Mutations in
P13K or in AKT, or changes in another protein called PTEN in this pathway can lead it to
become more active than is normal. This study investigates how effective MK-2206 is in
treating ovarian, fallopian tube, or primary peritoneal cancer where there are mutations in
P13K or AKT or low levels of PTEN.


MK-2206 will be taken orally once a week for four weeks (one cycle). Treatment will
continue for as long as a subject is benefitting from the study drug.

During each cycle subjects will have a physical exam, blood samples and an EKG (first 2
cycles). Every 2 cycles a CT scan or MRI of chest, stomach area, and pelvis will be
performed. Optional tumor biopsies may be performed.

Inclusion Criteria:

- Grade 2 or 3 ovarian, fallopian tube, or primary peritoneal cancer

- Evidence of a defect in the P13K/AKT pathway

- Prior platinum-based chemotherapy

- Life expectancy > 6 months

- Normal organ and marrow function

- Toxicities from prior therapy resolved

- Able to tolerate oral medications

Exclusion Criteria:

- Pregnant or breastfeeding

- Receiving other study agents

- Brain metastases

- Subjects requiring insulin for control of hyperglycemia

- Prolonged QTc interval

- Preexisting significant heart block or bradycardia due to cardiac disease

- Uncontrolled intercurrent illness

- Bowel obstruction

- Dependency on IV hydration or TPN

- History of a different malignancy unless disease free for the last 5 years

- HIV-positive on combination antiretroviral therapy
We found this trial at
5
sites
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
1275 York Avenue
New York, New York 10065
212-639-2000
Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private...
?
mi
from
New York, NY
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
2014 Washington St
Newton, Massachusetts 02462
(617) 243-6000
Newton-Wellesley Hospital A comprehensive medical center located right in Newton on Washington Street, Newton-Wellesley Hospital...
?
mi
from
Newton, MA
Click here to add this to my saved trials